Strategies to maximize influenza vaccine impact in older adults
Copyright © 2018 Elsevier Ltd. All rights reserved..
Older adults are disproportionately affected by influenza morbidity and mortality. In most high income countries, influenza vaccine policies target persons age ≥65 years for influenza vaccination. Many low-resource settings do not utilize seasonal influenza vaccination. Barriers to influenza prevention among older adults around the globe are multiple and some vary between high- and low-resource settings. To maximize influenza prevention in the older adult population, gaps in influenza vaccination coverage and improvements in vaccine efficacy are needed. The focus of this article is on the data for currently available vaccine strategies to maximize influenza vaccine impact, with a focus on high-resource settings. We also discuss novel influenza vaccine strategies needed for older adults worldwide.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Vaccine - 36(2018), 40 vom: 25. Sept., Seite 5940-5948 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Whitaker, Jennifer A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.02.2019 Date Revised 15.02.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.vaccine.2018.08.040 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM287919641 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM287919641 | ||
| 003 | DE-627 | ||
| 005 | 20231225055125.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.vaccine.2018.08.040 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0959.xml |
| 035 | |a (DE-627)NLM287919641 | ||
| 035 | |a (NLM)30153995 | ||
| 035 | |a (PII)S0264-410X(18)31169-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Whitaker, Jennifer A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Strategies to maximize influenza vaccine impact in older adults |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2019 | ||
| 500 | |a Date Revised 15.02.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2018 Elsevier Ltd. All rights reserved. | ||
| 520 | |a Older adults are disproportionately affected by influenza morbidity and mortality. In most high income countries, influenza vaccine policies target persons age ≥65 years for influenza vaccination. Many low-resource settings do not utilize seasonal influenza vaccination. Barriers to influenza prevention among older adults around the globe are multiple and some vary between high- and low-resource settings. To maximize influenza prevention in the older adult population, gaps in influenza vaccination coverage and improvements in vaccine efficacy are needed. The focus of this article is on the data for currently available vaccine strategies to maximize influenza vaccine impact, with a focus on high-resource settings. We also discuss novel influenza vaccine strategies needed for older adults worldwide | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, U.S. Gov't, P.H.S. | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Adjuvants | |
| 650 | 4 | |a Adult | |
| 650 | 4 | |a Aged | |
| 650 | 4 | |a Immunocompromised host | |
| 650 | 4 | |a Immunologic | |
| 650 | 4 | |a Influenza vaccines | |
| 650 | 4 | |a Influenza, Human | |
| 650 | 4 | |a Vaccination | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 700 | 1 | |a von Itzstein, Mitchell S |e verfasserin |4 aut | |
| 700 | 1 | |a Poland, Gregory A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Vaccine |d 1985 |g 36(2018), 40 vom: 25. Sept., Seite 5940-5948 |w (DE-627)NLM012600105 |x 1873-2518 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2018 |g number:40 |g day:25 |g month:09 |g pages:5940-5948 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.vaccine.2018.08.040 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2018 |e 40 |b 25 |c 09 |h 5940-5948 | ||